Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency.

Ricordel M, Foloppe J, Antoine D, Findeli A, Kempf J, Cordier P, Gerbaud A, Grellier B, Lusky M, Quemeneur E, Erbs P.

Cancers (Basel). 2018 Jul 10;10(7). pii: E231. doi: 10.3390/cancers10070231.

2.

Cowpox Virus: A New and Armed Oncolytic Poxvirus.

Ricordel M, Foloppe J, Pichon C, Sfrontato N, Antoine D, Tosch C, Cochin S, Cordier P, Quemeneur E, Camus-Bouclainville C, Bertagnoli S, Erbs P.

Mol Ther Oncolytics. 2017 Aug 24;7:1-11. doi: 10.1016/j.omto.2017.08.003. eCollection 2017 Dec 15.

3.

Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.

Remy-Ziller C, Thioudellet C, Hortelano J, Gantzer M, Nourtier V, Claudepierre MC, Sansas B, Préville X, Bendjama K, Quemeneur E, Rittner K.

Hum Vaccin Immunother. 2018 Jan 2;14(1):140-145. doi: 10.1080/21645515.2017.1373921. Epub 2017 Oct 18.

4.

Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC.

Tosch C, Bastien B, Barraud L, Grellier B, Nourtier V, Gantzer M, Limacher JM, Quemeneur E, Bendjama K, Préville X.

J Immunother Cancer. 2017 Sep 19;5(1):70. doi: 10.1186/s40425-017-0274-x.

5.

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer.

Bendjama K, Quemeneur E.

Hum Vaccin Immunother. 2017 Sep 2;13(9):1997-2003. doi: 10.1080/21645515.2017.1334746. Epub 2017 Aug 28.

6.

Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy.

Fend L, Yamazaki T, Remy C, Fahrner C, Gantzer M, Nourtier V, Préville X, Quéméneur E, Kepp O, Adam J, Marabelle A, Pitt JM, Kroemer G, Zitvogel L.

Cancer Res. 2017 Aug 1;77(15):4146-4157. doi: 10.1158/0008-5472.CAN-16-2165. Epub 2017 May 23.

7.

Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen.

Hillman GG, Reich LA, Rothstein SE, Abernathy LM, Fountain MD, Hankerd K, Yunker CK, Rakowski JT, Quemeneur E, Slos P.

J Immunother Cancer. 2017 Jan 17;5:4. doi: 10.1186/s40425-016-0204-3. eCollection 2017.

8.

[Nursing practice within the French national gendarmerie intervention group].

Fressancourt Y, Quémeneur É, Bertho K, Dubourg O.

Rev Infirm. 2016 Nov;65(225):22-24. doi: 10.1016/j.revinf.2016.08.025. French.

PMID:
27968965
9.

Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition.

Kleinpeter P, Fend L, Thioudellet C, Geist M, Sfrontato N, Koerper V, Fahrner C, Schmitt D, Gantzer M, Remy-Ziller C, Brandely R, Villeval D, Rittner K, Silvestre N, Erbs P, Zitvogel L, Quéméneur E, Préville X, Marchand JB.

Oncoimmunology. 2016 Sep 9;5(10):e1220467. eCollection 2016.

10.

Medical causes of temporary or definitive leaves from a French counterterrorist unit pre-internship.

Thabouillot O, Roffi R, Bertho K, Ramon F, Commeau D, Fressancourt Y, Quemeneur E, Roche NC, Dubourg O.

J R Army Med Corps. 2017 Apr;163(2):132-134. doi: 10.1136/jramc-2016-000644. Epub 2016 Jul 13.

PMID:
27412359
11.

Characterization of UO2(2+) binding to osteopontin, a highly phosphorylated protein: insights into potential mechanisms of uranyl accumulation in bones.

Qi L, Basset C, Averseng O, Quéméneur E, Hagège A, Vidaud C.

Metallomics. 2014 Jan;6(1):166-76. doi: 10.1039/c3mt00269a.

PMID:
24327307
12.

Antibody-free detection of phosphoserine/threonine containing peptides by homogeneous time-resolved fluorescence.

Alpha-Bazin B, Quéméneur E.

Anal Chem. 2012 Nov 20;84(22):9963-70. doi: 10.1021/ac3021505. Epub 2012 Oct 30.

PMID:
23110758
13.

From cell to man: evaluation of osteopontin as a possible biomarker of uranium exposure.

Prat O, Ansoborlo E, Sage N, Cavadore D, Lecoix J, Kurttio P, Quemeneur E.

Environ Int. 2011 May;37(4):657-62. doi: 10.1016/j.envint.2011.01.004. Epub 2011 Feb 16.

PMID:
21324525
14.

Predicting the disruption by UO2(2+) of a protein-ligand interaction.

Pible O, Vidaud C, Plantevin S, Pellequer JL, Quéméneur E.

Protein Sci. 2010 Nov;19(11):2219-30. doi: 10.1002/pro.501.

15.

Characterisation of the purified human sodium/iodide symporter reveals that the protein is mainly present in a dimeric form and permits the detailed study of a native C-terminal fragment.

Huc-Brandt S, Marcellin D, Graslin F, Averseng O, Bellanger L, Hivin P, Quemeneur E, Basquin C, Navarro V, Pourcher T, Darrouzet E.

Biochim Biophys Acta. 2011 Jan;1808(1):65-77. doi: 10.1016/j.bbamem.2010.08.013. Epub 2010 Aug 23.

16.

One step immunochromatographic assay for the rapid detection of Alexandrium minutum.

Gas F, Baus B, Pinto L, Compere C, Tanchou V, Quéméneur E.

Biosens Bioelectron. 2010 Jan 15;25(5):1235-9. doi: 10.1016/j.bios.2009.09.033. Epub 2009 Oct 1.

PMID:
19857953
17.

Alterations in gene expression in cultured human cells after acute exposure to uranium salt: Involvement of a mineralization regulator.

Prat O, Bérenguer F, Steinmetz G, Ruat S, Sage N, Quéméneur E.

Toxicol In Vitro. 2010 Feb;24(1):160-8. doi: 10.1016/j.tiv.2009.07.035. Epub 2009 Aug 3.

PMID:
19654044
18.

Identification of uranyl binding proteins from human kidney-2 cell extracts by immobilized uranyl affinity chromatography and mass spectrometry.

Dedieu A, Bérenguer F, Basset C, Prat O, Quéméneur E, Pible O, Vidaud C.

J Chromatogr A. 2009 Jul 10;1216(28):5365-76. doi: 10.1016/j.chroma.2009.05.023. Epub 2009 May 18.

PMID:
19501829
19.

Urine proteomic profiling of uranium nephrotoxicity.

Malard V, Gaillard JC, Bérenguer F, Sage N, Quéméneur E.

Biochim Biophys Acta. 2009 Jun;1794(6):882-91. doi: 10.1016/j.bbapap.2009.01.010. Epub 2009 Feb 7.

PMID:
19336034
20.

The analysis of phosphoproteomes by selective labelling and advanced mass spectrometric techniques.

Amoresano A, Cirulli C, Monti G, Quemeneur E, Marino G.

Methods Mol Biol. 2009;527:173-90, ix. doi: 10.1007/978-1-60327-834-8_13. Review.

PMID:
19241013
21.

Design and characterization of immunogens for raising antibodies directed towards chelated alkali metals.

Safi S, Asfari Z, Leroy M, Basset C, Quéméneur E, Vidaud C, Hagège A.

Analyst. 2009 Feb;134(2):256-60. doi: 10.1039/b810356a. Epub 2008 Oct 23.

PMID:
19173046
22.

New formulae for folding catalysts make them multi-purpose enzymes.

Moutiez M, Guthapfel R, Gueguen P, Quéméneur E.

Biotechnol Bioeng. 1997 Dec 20;56(6):645-9. doi: 10.1002/(SICI)1097-0290(19971220)56:6<645::AID-BIT7>3.0.CO;2-N.

PMID:
18642336
23.

Autophosphorylated residues involved in the regulation of human chk2 in vitro.

Gabant G, Lorphelin A, Nozerand N, Marchetti C, Bellanger L, Dedieu A, Quéméneur E, Alpha-Bazin B.

J Mol Biol. 2008 Jul 11;380(3):489-503. doi: 10.1016/j.jmb.2008.04.053. Epub 2008 May 1.

PMID:
18538787
24.

Specific capture of uranyl protein targets by metal affinity chromatography.

Basset C, Dedieu A, Guérin P, Quéméneur E, Meyer D, Vidaud C.

J Chromatogr A. 2008 Mar 28;1185(2):233-40. doi: 10.1016/j.chroma.2008.01.081. Epub 2008 Feb 8.

PMID:
18308325
25.

High-affinity uranyl-specific antibodies suitable for cellular imaging.

Reisser-Rubrecht L, Torne-Celer C, Rénier W, Averseng O, Plantevin S, Quéméneur E, Bellanger L, Vidaud C.

Chem Res Toxicol. 2008 Feb;21(2):349-57. Epub 2007 Dec 22.

PMID:
18154273
26.

The checkpoint Saccharomyces cerevisiae Rad9 protein contains a tandem tudor domain that recognizes DNA.

Lancelot N, Charier G, Couprie J, Duband-Goulet I, Alpha-Bazin B, Quémeneur E, Ma E, Marsolier-Kergoat MC, Ropars V, Charbonnier JB, Miron S, Craescu CT, Callebaut I, Gilquin B, Zinn-Justin S.

Nucleic Acids Res. 2007;35(17):5898-912. Epub 2007 Aug 28.

27.

Global gene expression profiling in human lung cells exposed to cobalt.

Malard V, Berenguer F, Prat O, Ruat S, Steinmetz G, Quemeneur E.

BMC Genomics. 2007 Jun 6;8:147.

28.

Energy landscape of chelated uranyl: antibody interactions by dynamic force spectroscopy.

Odorico M, Teulon JM, Bessou T, Vidaud C, Bellanger L, Chen SW, Quéméneur E, Parot P, Pellequer JL.

Biophys J. 2007 Jul 15;93(2):645-54. Epub 2007 Apr 20.

29.

RASSF1C, an isoform of the tumor suppressor RASSF1A, promotes the accumulation of beta-catenin by interacting with betaTrCP.

Estrabaud E, Lassot I, Blot G, Le Rouzic E, Tanchou V, Quemeneur E, Daviet L, Margottin-Goguet F, Benarous R.

Cancer Res. 2007 Feb 1;67(3):1054-61.

30.

Structural consequences of binding of UO2(2+) to apotransferrin: can this protein account for entry of uranium into human cells?

Vidaud C, Gourion-Arsiquaud S, Rollin-Genetet F, Torne-Celer C, Plantevin S, Pible O, Berthomieu C, Quéméneur E.

Biochemistry. 2007 Feb 27;46(8):2215-26. Epub 2007 Feb 1.

PMID:
17266333
31.

Structural insights into protein-uranyl interaction: towards an in silico detection method.

Pible O, Guilbaud P, Pellequer JL, Vidaud C, Quéméneur E.

Biochimie. 2006 Nov;88(11):1631-8. Epub 2006 Jun 21.

PMID:
16815621
32.

Proteomic analysis of the response of human lung cells to uranium.

Malard V, Prat O, Darrouzet E, Bérenguer F, Sage N, Quéméneur E.

Proteomics. 2005 Nov;5(17):4568-80.

PMID:
16240288
33.

The thiol-disulfide oxidoreductase system in the cold-adapted bacterium Pseudoalteromonas haloplanktis TAC 125: discovery of a novel disulfide oxidoreductase enzyme.

Madonna S, Papa R, Birolo L, Autore F, Doti N, Marino G, Quemeneur E, Sannia G, Tutino ML, Duilio A.

Extremophiles. 2006 Feb;10(1):41-51. Epub 2005 Sep 23.

PMID:
16179963
34.

Ex vivo analysis of acinar and endocrine cell development in the human embryonic pancreas.

Castaing M, Duvillié B, Quemeneur E, Basmaciogullari A, Scharfmann R.

Dev Dyn. 2005 Oct;234(2):339-45.

35.

Quantitation of p53 nuclear relocation in response to stress using a yeast functional assay: effects of irradiation and modulation by heavy metal ions.

Godon C, Coullet S, Baus B, Alonso B, Davin AH, Delcuze Y, Marchetti C, Hainaut P, Kazmaier M, Quemeneur E.

Oncogene. 2005 Sep 22;24(42):6459-64.

PMID:
16007197
36.

Boundaries and physical characterization of a new domain shared between mammalian 53BP1 and yeast Rad9 checkpoint proteins.

Alpha-Bazin B, Lorphelin A, Nozerand N, Charier G, Marchetti C, Bérenguer F, Couprie J, Gilquin B, Zinn-Justin S, Quéméneur E.

Protein Sci. 2005 Jul;14(7):1827-39.

37.

Screening of human serum proteins for uranium binding.

Vidaud C, Dedieu A, Basset C, Plantevin S, Dany I, Pible O, Quéméneur E.

Chem Res Toxicol. 2005 Jun;18(6):946-53.

PMID:
15962929
38.

Industrial process proteomics: alfalfa protein patterns during wet fractionation processing.

Incamps A, Hély-Joly F, Chagvardieff P, Rambourg JC, Dedieu A, Linares E, Quéméneur E.

Biotechnol Bioeng. 2005 Aug 20;91(4):447-59.

PMID:
15948168
39.

STD and TRNOESY NMR studies on the conformation of the oncogenic protein beta-catenin containing the phosphorylated motif DpSGXXpS bound to the beta-TrCP protein.

Megy S, Bertho G, Gharbi-Benarous J, Evrard-Todeschi N, Coadou G, Ségéral E, Iehle C, Quéméneur E, Benarous R, Girault JP.

J Biol Chem. 2005 Aug 12;280(32):29107-16. Epub 2005 May 31.

40.

Deciphering structure and topology of conserved COG2042 orphan proteins.

Armengaud J, Dedieu A, Solques O, Pellequer JL, Quemeneur E.

BMC Struct Biol. 2005 Feb 8;5:3.

41.

Transcriptomic and proteomic responses of human renal HEK293 cells to uranium toxicity.

Prat O, Berenguer F, Malard V, Tavan E, Sage N, Steinmetz G, Quemeneur E.

Proteomics. 2005 Jan;5(1):297-306.

PMID:
15672453
42.

Copper-mediated homo-dimerisation for the HAH1 metallochaperone.

Tanchou V, Gas F, Urvoas A, Cougouluègne F, Ruat S, Averseng O, Quéméneur E.

Biochem Biophys Res Commun. 2004 Dec 10;325(2):388-94.

PMID:
15530404
43.

The Tudor tandem of 53BP1: a new structural motif involved in DNA and RG-rich peptide binding.

Charier G, Couprie J, Alpha-Bazin B, Meyer V, Quéméneur E, Guérois R, Callebaut I, Gilquin B, Zinn-Justin S.

Structure. 2004 Sep;12(9):1551-62.

44.

Mapping phosphorylation sites: a new strategy based on the use of isotopically labelled DTT and mass spectrometry.

Amoresano A, Marino G, Cirulli C, Quemeneur E.

Eur J Mass Spectrom (Chichester). 2004;10(3):401-12.

PMID:
15187299
45.

Escherichia coli thioredoxin inhibition by cadmium: two mutually exclusive binding sites involving Cys32 and Asp26.

Rollin-Genetet F, Berthomieu C, Davin AH, Quéméneur E.

Eur J Biochem. 2004 Apr;271(7):1299-309.

46.

1H, 13C and 15N resonance assignments of the region 1463-1617 of the mouse p53 binding protein 1 (53BP1).

Charier G, Alpha-Bazin B, Couprie J, Callebaut I, Bérenguer F, Quémeneur E, Gilquin B, Zinn-Justin S.

J Biomol NMR. 2004 Mar;28(3):303-4. No abstract available.

PMID:
14752266
47.

Label-retaining cells in the rat pancreas: location and differentiation potential in vitro.

Duvillié B, Attali M, Aiello V, Quemeneur E, Scharfmann R.

Diabetes. 2003 Aug;52(8):2035-42.

48.

Description of the topographical changes associated to the different stages of the DsbA catalytic cycle.

Vinci F, Couprie J, Pucci P, Quéméneur E, Moutiez M.

Protein Sci. 2002 Jul;11(7):1600-12.

49.

Slow folding of three-fingered toxins is associated with the accumulation of native disulfide-bonded intermediates.

Ruoppolo M, Talamo F, Pucci P, Moutiez M, Quèmèneur E, Mènez A, Marino G.

Biochemistry. 2001 Dec 18;40(50):15257-66.

PMID:
11735408
50.

Tailoring new enzyme functions by rational redesign.

Cedrone F, Ménez A, Quéméneur E.

Curr Opin Struct Biol. 2000 Aug;10(4):405-10. Review.

PMID:
10981626

Supplemental Content

Loading ...
Support Center